25 completed, 4 withdrawn, 3 terminated, 1 active not recruiting. 34 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 34 | Completed 25, Withdrawn 4, Terminated 3, Active not recruiting 1, Unknown 1 |
Follow Interferon beta-1a: new trials by email Literature Review of Interferon beta-1a trials Research Report on Interferon beta-1a
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Interferon Beta 1a in Hospitalized COVID-19 Patients Interferon Beta-1A, Lopinavir / Ritonavir, Single Dose of Hydroxychloroquine - COVID-19 | Phase 4 | Unknown | Shahid Beheshti University of Medical Sciences | 40 | 2020-04-15 | 2020-04-20 |
| Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS Early Highly Effective Therapies Group, Escalation Therapies Group - Multiple Sclerosis, Relapsing-Remitting | Phase 4 | Active not recruiting | The Cleveland Clinic | 800 | 2019-01-03 | 2026-08-31 |
| Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy peginterferon beta-1a, interferon beta-1a, interferon beta-1b - Relapsing Remitting Multiple Sclerosis | Phase 4 | Completed | Biogen | 80 | 2017-01-30 | 2020-11-25 |
| Effectiveness of Rebif® in Clinically Isolated Syndrome and Relapsing Multiple Sclerosis Using RebiSmart™ Rebif - Relapsing Multiple Sclerosis, Clinically Isolated Syndrome | Phase 4 | Completed | Merck KGaA, Darmstadt, Germany | 106 | 2014-12-31 | 2018-03-30 |
| Transition to Peginterferon Beta-1a (BIIB017) From Subcutaneous Interferon Therapy Interferon Beta, BIIB017 (Peginterferon beta-1a) - Relapsing Multiple Sclerosis | Phase 4 | Withdrawn | Biogen | 2014-10-01 | 2014-11-17 | |
| RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate Rebif® - Multiple Sclerosis | Phase 4 | Terminated | EMD Serono | 1 | 2014-06-01 | 2017-01-23 |
| A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis Rebif® - Multiple Sclerosis, Relapsing-Remitting | Phase 4 | Completed | Merck KGaA, Darmstadt, Germany | 200 | 2014-05-31 | 2018-09-20 |
| A Phase 4 Study to Assess the Impact of Patient Support Program on Health Related Quality of Life and Adherence in Subjects With Relapsing-Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart™ Device Rebif® - Multiple Sclerosis, Relapsing-Remitting | Phase 4 | Completed | Merck KGaA, Darmstadt, Germany | 93 | 2013-02-28 | 2017-08-24 |
| Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC) Fingolimod, Interferon beta - 1a (IFN), Glatiramer acetate (GA) - Relapsing Remitting Multiple Sclerosis | Phase 4 | Completed | Novartis Pharmaceuticals | 298 | 2012-01-01 | 2014-08-08 |
| Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change Fingolimod, Standard MS DMT - Relapsing Remitting Multiple Sclerosis | Phase 4 | Completed | Novartis Pharmaceuticals | 61 | 2011-05-01 | 2015-06-22 |
| A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis Fingolimod, Standard MS DMTs - Relapsing Forms of Multiple Sclerosis | Phase 4 | Completed | Novartis Pharmaceuticals | 1053 | 2010-08-01 | 2014-02-10 |
| Rebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot Trial Rebif - Multiple Sclerosis | Phase 4 | Completed | EMD Serono | 38 | 2010-06-30 | 2018-02-23 |
| A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-a TYSABRI and AVONEX - Relapsing-remitting Multiple Sclerosis | Phase 4 | Withdrawn | Biogen | 2008-11-01 | 2024-06-03 | |
| How Side Effects of Avonex Are Affected by Gradually Increasing to Full Dose vs Starting at Full Dose Interferon beta-1a - Relapsing Remitting Multiple Sclerosis | Phase 4 | Terminated | Biogen | 19 | 2007-06-01 | 2008-09-04 |
| Safety Study in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Receiving Betaferon or Rebif Betaferon/Betaseron, Rebif - Relapsing-remitting Multiple Sclerosis | Phase 4 | Completed | Bayer | 220 | 2006-03-01 | 2013-10-21 |
| Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis Interferon-beta-1a, Simvastatin, Placebo - Multiple Sclerosis | Phase 4 | Completed | Biogen | 380 | 2006-02-01 | 2010-10-15 |
| A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone Interferon beta-1a (Rebif) - Multiple Sclerosis, Relapsing-Remitting | Phase 4 | Completed | Merck KGaA, Darmstadt, Germany | 30 | 2005-12-01 | 2014-02-27 |
| Evaluation of Emotional Disorders During Treatment by Interferon Beta in Relapsing-remitting Multiple Sclerosis Patients Interferon beta-1a - Multiple Sclerosis, Relapsing, Remitting | Phase 4 | Completed | Merck KGaA, Darmstadt, Germany | 79 | 2005-01-01 | 2013-12-27 |
| Implementation Study of Treatment Optimization Recommendations on Relapsing-Remitting Multiple Sclerosis (RR MS) Subjects Rebif - Relapsing-Remitting Multiple Sclerosis | Phase 4 | Withdrawn | EMD Serono | 2004-11-01 | 2013-08-06 | |
| EARLY IFNB-1a and Simvastatin Combination Therapy in Clinically Isolated Syndrome Suggestive of Multiple Sclerosis Avonex/Zocor - Multiple Sclerosis | Phase 4 | Completed | University of North Carolina | 30 | 2004-09-01 | 2008-03-05 |
Showing 20 of 34. Sign in to see all of them.
Multiple Sclerosis (19) · Multiple Sclerosis, Relapsing-Remitting (18) · Optic Neuritis (2) · COVID-19 (1) · Cerebellar Diseases (1) · Demyelinating Diseases (1) · Myelitis (1) · Myelitis, Transverse (1) · Neuritis (1) · Recurrence (1)
Biogen (12) · Merck KGaA, Darmstadt, Germany (6) · EMD Serono (4) · Novartis Pharmaceuticals (3) · MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute (2) · Bayer (1) · Beth Israel Deaconess Medical Center (1) · Louisiana State University Health Sciences Center Shreveport (1) · Shahid Beheshti University of Medical Sciences (1) · Teva Branded Pharmaceutical Products R&D, Inc. (1) · The Cleveland Clinic (1) · University of North Carolina (1)
United States (9) · Germany (4) · United Kingdom (4) · Sweden (3) · Australia (2) · Belgium (2) · Canada (2) · Denmark (2) · Finland (2) · France (2) · Italy (2) · Netherlands (2) · Russia (2) · Switzerland (2) · Argentina (1)
Alireza Minagar, MD (1) · Bettina Stubinski, M.D. (1) · Bruno Brochet, MD, Prof. (1) · Daniel Ontaneda, MD, MSc (1) · Fernando Dangond, MD (1) · Helene Brooks (1) · Ilad Alavi Darazam, MD (1) · Minoosh Shabani, MD (1) · Mohammadreza Haji Esmaelie, MD (1)
PMID 18071030, PMID 18789766, PMID 20542736, PMID 21742556, PMID 23647445, PMID 24625687, PMID 25424122, PMID 26265273, PMID 26265274, PMID 26559139, PMID 31276502, PMID 42218617
2005 (1), 2014 (1), 2016 (1)